Taos Therapeutics, Inc.
CEO Richard Gadomski MD brings clinical, academic and neuroscience expertise to a new, innovative pharmaceutical solution.
About Taos Therapeutics, Inc.
Our Mission
- Taos Therapeutics, led by Bob Munday & Dr. Richard Gadomski, is developing the first agonist + guardrail therapy with digital adherence for Alcohol Use Disorder (AUD), a disease responsible for nearly 178,000 American deaths annually—significantly more than opioids and stimulants combined.
- Our sea change approach integrates proven generics with a smart device to deter relapse while addressing the fundamental neurobiology of AUD for the first time.
- With around 14 million U.S. adults affected and less than 3% receiving pharmacotherapy, the market opportunity is massive, especially considering that payer reimbursement models have already been proven in opioid addiction.
- We are pursuing a 505(b)(2) FDA pathway, leveraging existing safety data with clear 6–12 month de-risking milestones and accelerated approval.
- Taos is fortunate to have Bob Munday and his vast experience in pharmaceutical development heading up Ops!
- This transformational, first-in-class therapy has the potential for a direct line to M&A or IPO exit, establishing a new standard of care & watershed moment for AUD, as envisioned by Richard Gadomski MD.